Stoke Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
45 WIGGINS AVENUE, BEDFORD, MA, 01730
Mailing Address
45 WIGGINS AVENUE, BEDFORD, MA, 01730
Phone
781-430-8200
Fiscal Year End
1231
EIN
471144582
Financial Overview
FY2025
$418.43M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
Annual Reports
10-K
March 16, 2026
- Positive interim data for zorevunersen (STK-001) in Dravet syndrome, showing favorable safety and significantly reduced seizure frequency.
- Strong cash position of approximately $250.0 million, projected to fund operations into the first half of 2026.
Insider Trading
STRONG SELL
8 insiders
58 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.